Advertisement
IDXX vs SNN
Which Stock Would AI Choose? IDEXX Laboratories (IDXX) vs. Smith & Nephew (SNN) Stock Comparison
Key Takeaways
- IDXX has delivered stronger year-to-date (YTD) returns of approximately 16%, outpacing SNN's 4% amid recent market activity.
- IDXX trades at a premium price-to-earnings (P/E) ratio of 43x trailing twelve months (TTM), reflecting high growth expectations in veterinary diagnostics, compared to SNN's more attractive 22x P/E in medical devices.
- Recent product data for SNN highlights superior outcomes in cartilage repair and rotator cuff healing, bolstering sentiment in orthopaedics and wound care.
- IDXX anticipates robust Q1 earnings growth, driven by its Companion Animal Group, while SNN offers a 2.5% dividend yield for income-focused investors.
- Analyst targets suggest 28% upside for IDXX versus 16% for SNN, indicating relative optimism on IDXX's momentum.
Introduction
This stock comparison between IDXX and SNN examines two healthcare leaders: one in animal health diagnostics and the other in human medical devices. Both operate in resilient sectors benefiting from aging populations and pet ownership trends, yet they diverge in growth profiles and risk. Traders seeking momentum may eye IDXX's high-beta volatility, while value investors could favor SNN's stability and yield. This analysis highlights recent relative performance, business drivers, and market positioning to aid informed decision-making in the current environment.
IDXX Overview and Recent Performance
IDXX, or IDEXX Laboratories, develops diagnostic products for companion animals, livestock, poultry, dairy, and water testing. Its Companion Animal Group dominates revenue through point-of-care tests, reference labs, and software like VetConnect PLUS. In recent market activity, the stock has climbed 16% YTD, supported by consistent earnings beats and expansion in veterinary services. Anticipation for Q1 results has fueled sentiment, with projections for 12% revenue growth to $1.12 billion, driven by recurring consumables and international demand. Analyst adjustments, including UBS's neutral stance with a $640 target, reflect balanced views amid a 52-week range of $465-$770. Higher beta (1.57) amplifies market swings, but robust profitability—24.6% margins and 66% return on equity (ROE)—underpins resilience.
SNN Overview and Recent Performance
SNN, or Smith & Nephew, specializes in orthopaedics, sports medicine, ear-nose-throat (ENT), and advanced wound management devices, including knee/hip implants and arthroscopic tools. Recent weeks have seen positive data releases, such as five-year superiority for its AGILI-C cartilage implant and halved recovery times with REGENETEN for rotator cuff tears, enhancing procedural appeal. The stock's YTD gain of 4% lags broader indices, trading in a $28-$39 52-week range with lower beta (0.74) for stability. A 2.5% dividend yield attracts income seekers, complemented by 10% profit margins. Analyst targets average $36 amid Canaccord's hold rating, with focus shifting to fiscal Q1 results. Steady cash flow ($877 million levered free cash flow TTM) supports debt management in a competitive medtech landscape.
Trending AI Robots
Tickeron's Trending AI Robots page showcases 25 top-performing AI trading bots curated from over 350 available, each scanning thousands of tickers across stocks, ETFs, and crypto for real-time signals. These bots employ diverse strategies like trend trading, corridor take-profit/stop-loss (TP/SL), and fundamental analysis (FA), with timeframes from 5 minutes to 60 minutes. Standout performers include a semiconductor bot (+97% annualized return, 63% win rate), space imaging (+127% return, 51% win rate), and small-cap trend trader (+93% return, 59% win rate), boasting profit factors up to 11.7 and profit-to-drawdown ratios exceeding 17. Tailored to volatile conditions, they offer risk-managed copy trading via Signal, Virtual, or Brokerage Agents. Explore Trending AI Robots to identify bots aligning with your style and current market dynamics.
Head-to-Head Comparison
IDXX and SNN contrast in business models: IDXX's diagnostics emphasize high-margin consumables and software for pet/livestock health, fueling 10%+ revenue growth, while SNN relies on device implants and wound care with procedural volumes tied to elective surgeries. Growth drivers differ—IDXX benefits from pet humanization trends, SNN from orthopaedics innovation. Recent momentum favors IDXX (20% one-year return vs. 14%), but SNN offers lower risk via beta and dividend. IDXX's $45B market cap dwarfs SNN's $13B, with trade-offs in valuation (SNN cheaper on P/E, PEG) and sentiment (both positive but IDXX higher upside potential).
Tickeron AI Verdict
Tickeron's AI currently leans toward IDXX with higher probability for near-term outperformance, based on trend consistency in YTD gains, earnings catalysts, and superior growth metrics like ROE exceeding 65%. SNN provides stability and yield but trails in momentum and analyst conviction. Relative positioning favors IDXX's pet health exposure amid economic resilience.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDXX is a StrongBuy and SNN is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IDXX’s FA Score shows that 1 FA rating(s) are green whileSNN’s FA Score has 1 green FA rating(s).
- IDXX’s FA Score: 1 green, 4 red.
- SNN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IDXX’s TA Score shows that 4 TA indicator(s) are bullish while SNN’s TA Score has 4 bullish TA indicator(s).
- IDXX’s TA Score: 4 bullish, 4 bearish.
- SNN’s TA Score: 4 bullish, 4 bearish.
Price Growth
IDXX (@Medical Specialties) experienced а -0.24% price change this week, while SNN (@Medical/Nursing Services) price change was +3.10% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.28%. For the same industry, the average monthly price growth was +13.41%, and the average quarterly price growth was -7.34%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.83%. For the same industry, the average monthly price growth was +0.22%, and the average quarterly price growth was -16.42%.
Reported Earning Dates
IDXX is expected to report earnings on Aug 04, 2026.
SNN is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Medical Specialties (-3.28% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (-1.83% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| IDXX | SNN | IDXX / SNN | |
| Capitalization | 44.3B | 13.1B | 338% |
| EBITDA | 1.56B | 1.53B | 102% |
| Gain YTD | -16.905 | -5.291 | 320% |
| P/E Ratio | 41.37 | 21.38 | 194% |
| Revenue | 4.45B | 6.16B | 72% |
| Total Cash | 201M | 419M | 48% |
| Total Debt | 1.11B | 3.45B | 32% |
IDXX | SNN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 11 | 53 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 82 Overvalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 92 | 100 | |
SMR RATING 1..100 | 16 | 78 | |
PRICE GROWTH RATING 1..100 | 60 | 58 | |
P/E GROWTH RATING 1..100 | 66 | 84 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SNN's Valuation (4) in the Medical Specialties industry is significantly better than the same rating for IDXX (82). This means that SNN’s stock grew significantly faster than IDXX’s over the last 12 months.
IDXX's Profit vs Risk Rating (92) in the Medical Specialties industry is in the same range as SNN (100). This means that IDXX’s stock grew similarly to SNN’s over the last 12 months.
IDXX's SMR Rating (16) in the Medical Specialties industry is somewhat better than the same rating for SNN (78). This means that IDXX’s stock grew somewhat faster than SNN’s over the last 12 months.
SNN's Price Growth Rating (58) in the Medical Specialties industry is in the same range as IDXX (60). This means that SNN’s stock grew similarly to IDXX’s over the last 12 months.
IDXX's P/E Growth Rating (66) in the Medical Specialties industry is in the same range as SNN (84). This means that IDXX’s stock grew similarly to SNN’s over the last 12 months.
| IDXX | SNN | |
|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 57% |
| Stochastic ODDS (%) | 3 days ago 63% | 3 days ago 61% |
| Momentum ODDS (%) | 3 days ago 57% | 3 days ago 54% |
| MACD ODDS (%) | 3 days ago 65% | 3 days ago 52% |
| TrendWeek ODDS (%) | 3 days ago 71% | 3 days ago 54% |
| TrendMonth ODDS (%) | 3 days ago 72% | 3 days ago 61% |
| Advances ODDS (%) | 4 days ago 60% | 4 days ago 56% |
| Declines ODDS (%) | 12 days ago 69% | 6 days ago 58% |
| BollingerBands ODDS (%) | 3 days ago 61% | 3 days ago 55% |
| Aroon ODDS (%) | 3 days ago 80% | 3 days ago 61% |
Advertisement
SNN and
Correlation & Price change
A.I.dvisor indicates that over the last year, SNN has been loosely correlated with OFIX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if SNN jumps, then OFIX could also see price increases.
| Ticker / NAME | Correlation To SNN | 1D Price Change % | ||
|---|---|---|---|---|
| SNN | 100% | -0.78% | ||
| OFIX - SNN | 47% Loosely correlated | -0.48% | ||
| GEHC - SNN | 43% Loosely correlated | +1.35% | ||
| STAA - SNN | 42% Loosely correlated | +0.44% | ||
| TCMD - SNN | 39% Loosely correlated | +0.91% | ||
| ALC - SNN | 39% Loosely correlated | +0.35% | ||
More | ||||